Published in Br J Clin Pharmacol on November 01, 2002
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol (2007) 1.13
Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J (2009) 1.08
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol (2003) 0.90
Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. Eur J Clin Pharmacol (2010) 0.88
Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. Eur J Clin Pharmacol (2005) 0.81
Coffee intake and CYP1A2*1F genotype predict breast volume in young women: implications for breast cancer. Br J Cancer (2008) 0.80
PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics (2012) 0.80
CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. Eur J Clin Pharmacol (2016) 0.79
Polymorphisms in heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk. Int J Mol Epidemiol Genet (2012) 0.77
quantitative assessment of the influence of cytochrome P450 1A2 gene polymorphism and colorectal cancer risk. PLoS One (2013) 0.77
Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal (1999) 9.80
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57
Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther (1991) 1.76
Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med (2000) 1.57
Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics (1995) 1.50
Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos (1987) 1.45
Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol (1999) 1.43
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics (1994) 1.39
A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther (1987) 1.37
Maternal cotinine level during pregnancy and birthweight for gestational age. Int J Epidemiol (1998) 1.29
A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol (1988) 1.28
Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol (1989) 1.24
Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics (1999) 1.23
Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol (1985) 1.17
Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res (1999) 1.13
Effect of pregnancy on the pharmacokinetics of caffeine. Eur J Clin Pharmacol (1981) 1.12
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol (1994) 1.11
Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis (1992) 1.09
Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics (2001) 1.07
The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther (2001) 1.02
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry (2000) 0.98
A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet (1997) 0.97
Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics (1996) 0.96
A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol (1998) 0.95
A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev (1995) 0.92
Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther (1990) 0.92
Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther (1990) 0.92
Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics (2000) 0.91
Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol (2000) 0.90
Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos (1999) 0.88
Caffeine metabolism and the risk of spontaneous abortion of normal karyotype fetuses. Obstet Gynecol (2001) 0.87
Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit (1996) 0.87
Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol (1999) 0.86
Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet (2001) 0.85
Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet (2000) 0.83
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit (2000) 0.83
Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol (2001) 0.81
Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR. DNA Cell Biol (1998) 0.77
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum (2006) 5.03
Outcomes of pregnancy after bariatric surgery. N Engl J Med (2015) 4.66
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol (2002) 3.72
Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ (2004) 3.67
Small-intestinal histopathology and mortality risk in celiac disease. JAMA (2009) 3.35
Maternal obesity and risk of preterm delivery. JAMA (2013) 3.14
Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation (2006) 3.08
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum (2009) 2.97
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet (2002) 2.72
Cigarette smoking and the male-female sex ratio. Fertil Steril (2003) 2.69
Hysterectomy and risk of stress-urinary-incontinence surgery: nationwide cohort study. Lancet (2007) 2.52
Environmental tobacco smoke and risk of spontaneous abortion. Epidemiology (2006) 2.51
Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ (2003) 2.28
Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. Eur J Clin Pharmacol (2003) 2.27
Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab (2008) 2.19
Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial. BMJ (2009) 2.06
Mortality within 2 years after surgery in relation to low intraoperative bispectral index values and preexisting malignant disease. Anesth Analg (2009) 2.04
A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis (2013) 2.02
Perinatal risk factors for ischemic heart disease: disentangling the roles of birth weight and preterm birth. Circulation (2008) 1.87
Low risk of gastrointestinal cancer among patients with celiac disease, inflammation, or latent celiac disease. Clin Gastroenterol Hepatol (2011) 1.85
UVB upregulates the antimicrobial protein hCAP18 mRNA in human skin. J Invest Dermatol (2005) 1.84
Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology (2010) 1.83
Risks of stress urinary incontinence and pelvic organ prolapse surgery in relation to mode of childbirth. Am J Obstet Gynecol (2011) 1.80
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics (2006) 1.80
Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers. BMC Gastroenterol (2009) 1.79
Perinatal outcomes after bariatric surgery: nationwide population based matched cohort study. BMJ (2013) 1.79
Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol (2004) 1.73
Pregnancy characteristics and maternal risk of breast cancer. JAMA (2005) 1.72
Self-reported nicotine exposure and plasma levels of cotinine in early and late pregnancy. Acta Obstet Gynecol Scand (2006) 1.72
Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol (2008) 1.70
Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. Intensive Care Med (2007) 1.69
Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab (2005) 1.68
End-stage renal disease patients on renal replacement therapy in the intensive care unit: short- and long-term outcome. Crit Care Med (2008) 1.68
Use of doping agents, particularly anabolic steroids, in sports and society. Lancet (2008) 1.63
Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol (2010) 1.61
Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. Nephrol Dial Transplant (2004) 1.58
Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation (2011) 1.56
Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol (2002) 1.56
Organochlorines in Swedish women: determinants of serum concentrations. Environ Health Perspect (2003) 1.52
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol (2011) 1.51
Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol (2011) 1.49
Long-term effects of botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol (2009) 1.48
Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population. Microbes Infect (2006) 1.45
Pelvic organ prolapse surgery following hysterectomy on benign indications. Am J Obstet Gynecol (2008) 1.43
Postoperative atrial fibrillation predicts cause-specific late mortality after coronary surgery. Scand Cardiovasc J (2014) 1.42
Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol (2006) 1.41
Malignant disease within 5 years after surgery in relation to duration of sevoflurane anesthesia and time with bispectral index under 45. Anesth Analg (2011) 1.40
Perinatal risk factors for diabetes in later life. Diabetes (2008) 1.36
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther (2005) 1.35
Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol (2004) 1.33
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci (2005) 1.30
Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome. Hum Reprod (2009) 1.30
Will an adverse pregnancy outcome influence the risk of continued smoking in the next pregnancy? Am J Obstet Gynecol (2006) 1.29
Maternal smoking and causes of very preterm birth. Acta Obstet Gynecol Scand (2005) 1.27
A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.23
Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst (2011) 1.23
Exposure to maternal smoking during pregnancy as a risk factor for tobacco use in adult offspring. Am J Epidemiol (2014) 1.22
Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol (2005) 1.22
SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol (2009) 1.21
Ramus or chin grafts for maxillary sinus inlay and local onlay augmentation: comparison of donor site morbidity and complications. Clin Implant Dent Relat Res (2003) 1.21
The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab (2007) 1.19
A clinical and histologic evaluation of implant integration in the posterior maxilla after sinus floor augmentation with autogenous bone, bovine hydroxyapatite, or a 20:80 mixture. Int J Oral Maxillofac Implants (2002) 1.18
Plasma folate levels and risk of spontaneous abortion. JAMA (2002) 1.17
Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res (2008) 1.16
Risk factors for Barrett's oesophagus: a population-based approach. Scand J Gastroenterol (2007) 1.16
Reducing in-hospital cardiac arrests and hospital mortality by introducing a medical emergency team. Intensive Care Med (2009) 1.15
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun (2002) 1.15
The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol (2003) 1.15
Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther (2003) 1.14
Health-related quality of life (EQ-5D) before and after orthopedic surgery. Acta Orthop (2010) 1.11
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics (2003) 1.11
Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device. Crit Care Med (2004) 1.11
Reconstruction of the atrophic edentulous maxilla with free iliac crest grafts and implants: a 3-year report of a prospective clinical study. Clin Implant Dent Relat Res (2007) 1.11
Bone reformation and implant integration following maxillary sinus membrane elevation: an experimental study in primates. Clin Implant Dent Relat Res (2006) 1.11
Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med (2013) 1.11
Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res (2009) 1.10
Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis (2007) 1.09
Thoracolumbar vertebral fractures in Sweden: an analysis of 13,496 patients admitted to hospital. Eur J Epidemiol (2010) 1.08
Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis (2014) 1.07
Abortion rate and contraceptive practices in immigrant and native women in Sweden. Scand J Public Health (2003) 1.06
Loco-regional recurrence from colon cancer: a population-based study. Ann Surg Oncol (2006) 1.06
Effect of caffeine exposure during pregnancy on birth weight and gestational age. Am J Epidemiol (2002) 1.05
Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol (2013) 1.04
Maternal age, anthropometrics and pregnancy oestriol. Paediatr Perinat Epidemiol (2002) 1.03
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol (2003) 1.03
Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol (2012) 1.03
A population-based case-control study of the familial risk of abdominal aortic aneurysm. J Vasc Surg (2008) 1.01
Evaluation of an algorithm ascertaining cases of osteonecrosis of the jaw in the Swedish National Patient Register. Clin Epidemiol (2013) 1.00
A prospective 1-year clinical and radiographic study of implants placed after maxillary sinus floor augmentation with bovine hydroxyapatite and autogenous bone. J Oral Maxillofac Surg (2002) 1.00
Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum (2006) 0.99